Security
Argen X NV Ordinary Shares (Netherlands) · ARGNF
ARGNFOTCCommon stockCurrentCIK 1697862Updated Oct 23, 2026
Name history
argenx N.V · through Apr 21, 2017
ARGNF price & chart
Loading TradingView…
OTC:ARGNF on TradingView ↗About the company
argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Profit or LossUSD | — | 1,292,035,000Source | 833,040,000Source | -295,053,000Source | -709,594,000Source |
| Additional Financial Items | |||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | — | -13,224,000Source | 383,000Source | 2,080,000Source | -12,000Source |
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesUSD | — | -12,390,000Source | -7,644,000Source | 4,411,000Source | 677,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | 248,079,000Source | 235,179,000Source | 232,974,000Source | 157,026,000Source |
| GeneralAndAdministrativeExpenseUSD | — | — | 1,055,337,000Source | 711,905,000Source | 472,132,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | — | 254,855,000Source | -7,801,000Source | 37,515,000Source | 24,141,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | 900,000Source | 392,000Source | 211,000Source | 851,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | 4,107,000Source | 7,638,000Source | 3,801,000Source | 4,165,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | 105,515,000Source | 66,500,000Source | 43,000,000Source | 102,986,000Source |
| ProceedsFromIssuingShares | —Source | — | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | 1,367,057,000Source | 1,055,337,000Source | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | — | — | 0.26Source | 0.26Source |
| BasicEarningsLossPerShareUSD per share | 21.08Source | 13.92Source | -5.16Source | -13.05Source |
| CurrentTaxExpenseIncomeUSD | 351,264,000Source | 53,462,000Source | 9,592,000Source | -27,162,000Source |
| DepreciationRightofuseAssetsUSD | 10,441,000Source | 5,759,000Source | 3,846,000Source | 2,949,000Source |
| DilutedEarningsLossPerShareUSD per share | 19.57Source | 12.78Source | -5.16Source | -13.05Source |
| EmployeeBenefitsExpenseUSD | 889,087,000Source | 735,908,000Source | 529,377,000Source | 396,750,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 128,000,000Source | 147,000,000Source | 164,000,000Source | 120,200,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedUSD | — | — | 40,000Source | 21,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedUSD | — | — | 1,517,000Source | 732,000Source |
| FinanceCostsUSD | 4,082,000Source | 2,464,000Source | 906,000Source | 3,906,000Source |
| FinanceIncomeUSD | 163,091,000Source | 157,509,000Source | 107,386,000Source | 27,665,000Source |
| GeneralAndAdministrativeExpenseUSD | — | 1,055,337,000Source | 711,905,000Source | 472,132,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | -13,428,000Source | -747,860,000Source | -9,443,000Source | -19,720,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 3,175,000Source | 2,072,000Source | 693,000Source | 1,343,000Source |
| OtherOperatingIncomeExpenseUSD | 1,423,000Source | — | — | — |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | 24,751,000Source | 12,330,000Source | 7,758,000Source | 5,406,000Source |
| ProfessionalFeesExpenseUSD | 238,228,000Source | 170,215,000Source | 108,820,000Source | — |
| ProfitLossAttributableToOwnersOfParentUSD | 1,292,035,000Source | 833,040,000Source | -295,053,000Source | -709,594,000Source |
| ProfitLossBeforeTaxUSD | 1,278,607,000Source | 85,180,000Source | -304,496,000Source | -729,314,000Source |
| ProfitLossFromOperatingActivitiesUSD | 1,053,806,000Source | -21,654,000Source | -425,049,000Source | -720,341,000Source |
| ResearchAndDevelopmentExpenseUSD | 1,364,132,000Source | 983,423,000Source | 859,492,000Source | 663,366,000Source |
Filing attachments
tm2627805d1_ex99-1.htm · 6-K · 2026-10-19
Exhibit 99.1 argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026 Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DM Patient improvements observed as early as Week 4 and sustained through 52 weeks Late-breaking oral presentation on Wednesday, November 1…
Read attachment ↗tm2627263d1_ex99-1.htm · 6-K · 2026-10-08
Exhibit 99.1 argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovati…
Read attachment ↗tm2627263d1_ex99-2.htm · 6-K · 2026-10-08
Exhibit 99.2 argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision is based on the recommendation from an Independent Dat…
Read attachment ↗tm2626570d1_ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. MG patients indicates the value of treating earlier with VYVGART Long-term d…
Read attachment ↗ef20081196_ex99-1.htm · 6-K · 2026-08-27
Exhibit 99.1 argenx Completes Acquisition of Forte Biosciences, Inc. Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 - 8:50 AM ET Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. (“Forte”) (Nasdaq: FBRX). The acquisition expands argenx’s portfolio of differentiated immunology medicines, adding…
Read attachment ↗tm2623372d1_ex99-1.htm · 6-K · 2026-08-17
Exhibit 99.1 argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease acti…
Read attachment ↗